A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
Latest Information Update: 26 Sep 2022
At a glance
- Drugs Recombinant complement factor H Gemini Therapeutics (Primary)
- Indications Dry age-related macular degeneration; Dry macular degeneration
- Focus Adverse reactions
- Acronyms ReGAtta
- Sponsors Gemini Therapeutics
- 22 Mar 2022 Status changed from active, no longer recruiting to discontinued due to no further benefit.
- 10 Jan 2022 Results published in the Media Release
- 15 Nov 2021 According to a Gemini Therapeutics media release, in October 2021, initial data from this study were presented at the 2nd Annual Dry AMD Therapeutic Development Summit: Uncovering the Largest Untapped Eyecare Market.